Novavax, Inc.NVAXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Trend
Trending higher, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
26.59%
Near historical average
Average (39q)
24.32%
Historical baseline
Range
High:743.96%
Low:-60.18%
CAGR
-4.7%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 26.59% |
| Q2 2025 | -12.71% |
| Q1 2025 | -14.79% |
| Q4 2024 | 19.75% |
| Q3 2024 | -18.50% |
| Q2 2024 | 15.39% |
| Q1 2024 | -43.73% |
| Q4 2023 | 55.04% |
| Q3 2023 | -51.60% |
| Q2 2023 | -11.18% |
| Q1 2023 | -4.17% |
| Q4 2022 | -15.26% |
| Q3 2022 | 5.06% |
| Q2 2022 | -24.47% |
| Q1 2022 | -60.18% |
| Q4 2021 | 135.91% |
| Q3 2021 | -28.47% |
| Q2 2021 | -3.71% |
| Q1 2021 | 47.72% |
| Q4 2020 | 36.42% |
| Q3 2020 | 743.96% |
| Q2 2020 | 106.25% |
| Q1 2020 | -42.42% |
| Q4 2019 | 57.65% |
| Q3 2019 | -38.81% |
| Q2 2019 | -14.25% |
| Q1 2019 | -18.29% |
| Q4 2018 | 5.05% |
| Q3 2018 | -7.22% |
| Q2 2018 | 0.06% |
| Q1 2018 | -10.36% |
| Q4 2017 | 18.62% |
| Q3 2017 | 6.62% |
| Q2 2017 | 4.27% |
| Q1 2017 | -26.31% |
| Q4 2016 | -3.55% |
| Q3 2016 | -18.37% |
| Q2 2016 | -5.87% |
| Q1 2016 | -9.16% |
| Q4 2015 | 171.89% |